Samit Hirawat, Bristol Myers Squibb EVP, CMO, Global Drug Development
June 3, 2022 07:32 AM EDTUpdated 09:49 AM
Deals

Bris­tol My­ers jumps in­to the M&A game with a $4B on­col­o­gy buy­out. And weary biotech an­a­lysts could­n't be any hap­pi­er

John Carroll

Editor & Founder

Bris­tol My­ers Squibb has nabbed Turn­ing Point Ther­a­peu­tics in a $4.1 bil­lion buy­out deal, just weeks af­ter the biotech post­ed an up­beat round of pos­i­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times